Email Alert | RSS    帮助

中国防痨杂志 ›› 2000, Vol. 22 ›› Issue (4): 214-216.

• 论著 • 上一篇    下一篇

含力克肺疾方案治疗耐多药结核病的疗效及评价

余德美;毛晓辉;张茜;赵琳;张全民;   

  1. 西安市结核病胸部肿瘤医院 陕西 710061;
  • 出版日期:2000-04-10 发布日期:2000-04-10

Therapeutic effect and evaluation of Pasiniazid on multi-drug resistant tuberculosis

YU De-mei,MAO Xiao-hui,ZHANG Qian,et al.   

  1. Xi’an Tuberculosis and Thoracic Tumor Hospital,Shanxi 710061
  • Online:2000-04-10 Published:2000-04-10

摘要: 目的 观察和评价含力克肺疾方案在耐多药结核病(MDR-TB)治疗中的疗效。方法 采用随机配对分组法将62例MDR-TB患者分为治疗组(M组,31例)和对照组(C组,31例)。化疗方案:M组以力克肺疾为主,另依据药敏试验选用3种以上敏感药或既往未用过的新药。C组不用力克肺疾,其它药物同M组。结果 治疗9个月后,M组涂阳阴转率61%,培阳阴转率65%;C组涂阳阴转率29%,培阳阴转率32%。痰菌阴转率M组显著高于C组(P<0.05)。M组病灶吸收及空洞关闭、缩小速度均显著高于C组(P<0.05)。2年复查,M组和C组痰菌复阳率分别为5%和20%。结论 含力克肺疾方案治疗MDR-TB,有助于痰菌阴转和病灶吸收好转,疗程结束后复发率低,疗效较为满意,值得临床上推广应用。

关键词: 耐多药结核病, 力克肺疾, 药物疗法

Abstract: Objective To observe and evaluate the therapeutic effect in the treatment of multi-drug resistant tuberculosis(MDR-TB)with Pasiniazid.Methods By random group-matching,62 cases with MDR-TB were divided into MDR-TB trial group(group M with 31 cases)and control group(group C with 31 cases).Chemotherapy regimen:In group M,Pasiniazid was the main drug,more 3 other sensitive drug or new drugs which were not used before were selected based on its susceptibility.In group C,Pasiniazid was not used,while other drugs were the same to the group M.Results 9 months later,the sputum negative conversion rate in smear was 61% and the rate in cuture was 65% in group M,29% and 32% respectively in group C.The conversion rate in group M is much higher than that in group C(P<0.05 ).The check in 2 years showed that the positive conversion rate was 5% in group M,and 20% in group C.Conclusion The therapeutic regimen with Pasiniazid is favourable to sputum negative conversion and vanishing of the foci,with lower relapse rate.Due to its satisfactory therapeutic effect,it is worth of clinic practice.

Key words: MDR-TB, Pasinizid, Drug therapy